Eric Blanchard practices corporate and securities law. He counsels domestic and foreign public and private companies, with an emphasis on those in the technology and biopharma industries, as well as investment banks. Eric advises clients on a variety of corporate transactions, including initial public offerings, follow-on equity offerings, pre-IPO financings, investment-grade, high-yield and convertible debt offerings, liability management transactions, proxy contests and acquisitions. He also represents public companies with respect to securities and disclosure issues and corporate governance matters.

Download full bio 


  • Cerevel Therapeutics – $253.8 Million Follow-on Offering and Concurrent $345.0 Million Rule 144A Convertible Notes Offering 

  • Verona Pharma – $150 Million Follow-on Offering 

  • The Clorox Company – $1.1 Billion Unsecured Senior Notes Offering 

  • Xometry – $287 Million Convertible Senior Notes Offering 

  • SOPHiA Genetics – $234 Million IPO 

  • View all

He has been absolutely brilliant. He is relaxed, measured, on top of all the issues and a delight to deal with. – Client Testimonial, Chambers USA

  • Columbus School of Law - The Catholic University of America
    JD, magna cum laude, 1999

  • University of Maryland
    BA, 1996

Admissions & Credentials

New York

Rankings & Accolades

    Chambers USA: Capital Markets: Debt & Equity

    Legal 500: Key Lawyer – Capital Markets: Equity Offerings